2024
Passenger gene co-amplifications create collateral therapeutic vulnerabilities in cancer
Bei Y, Bramé L, Kirchner M, Fritsche-Guenther R, Kunz S, Bhattacharya A, Rusu M, Gürgen D, Dubios F, Köppke J, Proba J, Wittstruck N, Sidorova O, González R, Garcia H, Brückner L, Xu R, Giurgiu M, Rodriguez-Fos E, Yu Q, Spanjaard B, Koche R, Schmitt C, Schulte J, Eggert A, Haase K, Kirwan J, Hagemann A, Mertins P, Dörr J, Henssen A. Passenger gene co-amplifications create collateral therapeutic vulnerabilities in cancer. Cancer Discovery 2024, 14: 492-507. PMID: 38197697, PMCID: PMC10911929, DOI: 10.1158/2159-8290.cd-23-1189.Peer-Reviewed Original ResearchMeSH KeywordsCell DeathHumansMechanistic Target of Rapamycin Complex 1Medical OncologyNeoplasmsOncogenesConceptsDEAD-box helicase 1Passenger genesTherapeutic vulnerabilitiesTricarboxylic acidCRISPR-Cas9 loss-of-function screensLoss-of-function screensCell death in vitroDisruption of mTORC1Death in vitroGene co-amplificationCancer cell linesCancer genomesHelicase 1Interaction partnersCancer dependenciesCollateral vulnerabilitiesTCA activityCo-amplificationDNA amplificationMTORC1 activityCancerPharmacological disruptionCancer biologyTarget discoveryCoamplification
2023
Elimusertib has anti-tumor activity in preclinical patient-derived pediatric solid tumor models
Pusch F, García H, Xu R, Gürgen D, Bei Y, Brückner L, Röefzaad C, von Stebut J, Bardinet V, Gonzalez R, Eggert A, Schulte J, Hundsdörfer P, Seifert G, Haase K, Schäfer B, Wachtel M, Kühl A, Ortiz M, Wengner A, Scheer M, Henssen A. Elimusertib has anti-tumor activity in preclinical patient-derived pediatric solid tumor models. Molecular Cancer Therapeutics 2023, 23: 507-519. PMID: 38159110, PMCID: PMC10985474, DOI: 10.1158/1535-7163.mct-23-0094.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsPediatric solid tumor modelsPreclinical antitumor activitySolid tumor modelsTumor modelStandard-of-care chemotherapyAntitumor activityInhibitor of ataxia telangiectasiaSolid tumor entitiesClinically meaningful responseAnti-tumor activityPreclinical activityRad3-related proteinTumor entitiesPediatric malignanciesAntitumor effectCancer entitiesResponse biomarkersSmall molecule inhibitorsClinical trialsElimusertibMeaningful responseAtaxia telangiectasiaResponse rateCell linesParallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells
Chamorro González R, Conrad T, Stöber M, Xu R, Giurgiu M, Rodriguez-Fos E, Kasack K, Brückner L, van Leen E, Helmsauer K, Dorado Garcia H, Stefanova M, Hung K, Bei Y, Schmelz K, Lodrini M, Mundlos S, Chang H, Deubzer H, Sauer S, Eggert A, Schulte J, Schwarz R, Haase K, Koche R, Henssen A. Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells. Nature Genetics 2023, 55: 880-890. PMID: 37142849, PMCID: PMC10181933, DOI: 10.1038/s41588-023-01386-y.Peer-Reviewed Original ResearchConceptsExtrachromosomal circular DNACircular DNAParallel sequencingCancer cellsIntercellular differencesFull-length mRNADNA elementsExtrachromosomal DNATranscriptome sequencingTranscriptional impactSingle cancer cellsEcDNAExpression differencesDNATranscriptomeCellsIntratumoral heterogeneityStructural heterogeneitySequenceStructural dynamicsMRNACancerRecombination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply